Portal de Periódicos da CAPES

Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia

2015; Wiley; Volume: 11; Issue: 8 Linguagem: Inglês

10.1016/j.jalz.2015.01.006

1552-5279

Marwan N. Sabbagh, Kewei Chen, Joseph Rogers, Adam Fleisher, Carolyn Liebsack, Dan Bandy, Christine M. Belden, Hillary Protas, Pradeep Thiyyagura, Xiaofen Liu, Auttawut Roontiva, Ji Luo, Sandra A. Jacobson, Michael Malek‐Ahmadi, Jessica Powell, Eric M. Reiman,

Chronic Disease Management Strategies

Abstract Introduction Down syndrome (DS) is associated with amyloid b (Ab) deposition. Methods We characterized imaging measurements of regional fibrillar Ab burden, cerebral metabolic rate for glucose (rCMRgl), gray matter volumes (rGMVs), and age associations in 5 DS with dementia (DS/AD1), 12 DS without dementia (DS/AD2), and 9 normal controls (NCs). Results There were significant group differences in mean standard uptake value ratios (SUVRs) for florbetapir with DS/AD1 having the highest, followed by DS/AD2, followed by NC. For [18F]‐fluorodeoxyglucose positron emission tomography, posterior cingulate rCMRgl in DS/AD1 was significantly reduced compared with DS/AD2 and NC. For volumetric magnetic resonance imaging (vMRI), hippocampal volumes were significantly reduced for the DS/AD1 compared with DS/AD2 and NC. Age‐related SUVR increases and rCMRgl reductions were greater in DS participants than in NCs. Discussion DS is associated with fibrillar Ab, rCMRgl, and rGMV alterations in the dementia stage and before the presence of clinical decline. This study provides a foundation for the studies needed to inform treatment and prevention in DS.